SIBANNAC, INC. TO BEGIN MANUFACTURING INVENTORY FOR ITS NEW FLAGSHIP BRAND
Sibannac, Inc. (OTC Pink: SNNC) continues its transformation into a multi-faceted wellness brand, operating from its Scottsdale facility. The company focuses on contract manufacturing and aims to build a sustainable brand in the alternative wellness space. Key initiatives include developing Kratom products and leveraging partnerships for enhanced marketing and distribution. Additionally, the firm has secured a licensing agreement for Copper 1 raw material, aiding its product formulation and meeting consumer health needs. Sibannac is also pursuing clinical trials for Copper 1 while expanding its market reach.
- Sibannac is developing a line of Kratom products and evaluating new in-house production equipment.
- The company has a licensing agreement with Mitosynergy for Copper 1, targeting consumer health needs.
- Partnership with Lifetime Branding aims to boost market awareness and expand distribution channels.
- None.
Scottsdale, Arizona, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the “Company”), announced the following:
The Company is continuing its evolution into a multi-faceted and vertically integrated next-generation wellness brand. We have developed several products in our Scottsdale facility, following extensive research and sample testing.
The Company’s, The Campus Co., is the operational platform containing the infrastructure behind all branding, product development, sourcing, manufacturing, sales, and distribution efforts. Most manufacturing operations are being done out of the company’s lab in Scottsdale, in its Food-Grade FDA registered facility.
Our immediate and short-term operational focus includes our marketing resources with Lifetime Branding to penetrate the contract manufacturing and fee-for-service channels. The goal is to gain awareness in the marketplace as a manufacturing and logistics solution for industry brands willing to pay premiums for smaller runs.
The Lifetime team brings incalculable value to Sibannac, as its founder, Eric Stoll, has a proven track record in ground-up brand building. We believe there is now unbounded opportunity to create a sustainable brand in the alternative wellness space. Eric has an impressive track record not only advancing already established brands for some of the Fortune 500, but also creating new brands from the ground up with a particular focus in the nutraceutical space. Mr. Stoll and his team of marketing professionals and formulators are set to launch Sibannac’s wellness brand into key market segments, including wholesale, retail and direct-to-consumer. His previous experience includes building the Super Candy brand to 25,000 doors in three years and was carried in Walmart, Target, Costco, Whole Foods and leading pharmacies.
Kratom
Sibannac is developing a line of Kratom products currently and evaluating new equipment to bring Kratom production fully in-house. Kratom is the common name for Mitragyna Speciosa Korthals, a tree indigenous to Southeast Asia. The main compound in Kratom, Mitragynine, has been used for hundreds of years in Asia as a natural, plant-based solution to manage pain, anxiety and sleep. Kratom is currently popular with chronic pain patients seeking alternatives to opioid prescription medication.
Delta-8 and Delta-9 THC
All Delta-8 and the more commonly known Delta-9 THC compounds in our products are derived from certified hemp. The market for hemp-derived THC products is growing at an immense pace as products can be shipped directly to the consumer or purchased at retail outside of the licensed marijuana space.
Copper 1
Sibannac has a licensing agreement with Mitosynergy to provide the Company with Copper 1 raw material for formulation into finished goods. The products will be formulated to address some of the most common consumer needs, chief among them improved immune response. Mitosynegy has been awarded multiple U.S. patents for molecular compounds for bioavailable coppers, namely Cuprous Nicotinic Acid. These patented compounds involve the only known bioavailable Copper 1 in the Copper 1 oxidative state. (For additional information, Patent Nos.: WO2016/037181 and 20150224112. Videos: https://youtu.be/2jtSDvxunYI and https://youtu.be/N9YFkLvy6GY.
Mitosynergy has performed a human study on the Copper Niacin compound and submitted results to the Food and Drug Administration (“FDA”). In response, the FDA issued a No Objection Letter: #910, allowing the Copper compound to be marketed as an Initial New Dietary Ingredient (“IND”). The Company will now be aiding Mitosynergy in securing third-party funding for clinical trials.
Cautionary Note Regarding Forward-Looking Statements.
This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Sibannac, Inc. (the “Company”), its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
Media Contact: IR@theCampusCo.com
FAQ
What is Sibannac's focus as announced in the latest PR?
What products is Sibannac developing?
What is the significance of the licensing agreement with Mitosynergy?
How does Lifetime Branding contribute to Sibannac's strategy?
